Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 9/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | PDE5A | O76074 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | HTT | P42858 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | METAP1 | P53582 | 1/20 | 0.45 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23748378 | 0.83 | PDE5A (0.50) | GBA1KDM4EKMT2AMEN1ALDH1A1 | |
| SCHEMBL23748372 | 0.81 | PDE5A (0.53) | GBA1KDM4EKMT2AALDH1A1PDE5A | |
| SCHEMBL1083938 | 0.80 | KMT2A (0.58) | GBA1KMT2AMAPTMEN1ALDH1A1 | |
| SCHEMBL23748379 | 0.80 | METAP1 (0.47) | GBA1KDM4EKMT2AALDH1A1PDE5A | |
| SCHEMBL26599007 | 0.79 | APP (0.64) | GBA1KDM4EKMT2APDE5ALMNA | |
| SCHEMBL23747962 | 0.79 | GBA1 (1.00) | GBA1KDM4EKMT2AMAPTMEN1 | |
| SCHEMBL17800023 | 0.76 | GBA1 (0.72) | GBA1KDM4EKMT2AMAPTMEN1 | |
| SCHEMBL26598931 | 0.76 | PDE5A (0.53) | GBA1KDM4EKMT2APDE5ALMNA | |
| SCHEMBL7287132 | 0.75 | KMT2A (1.00) | GBA1KDM4EKMT2AMAPTMEN1 | |
| SCHEMBL30125338 | 0.75 | GBA1 (0.66) | GBA1KDM4EKMT2AMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | TroBio Therapeutics Pty Ltd (AU) | 2023-10-26 | — | — | US | disclosed |
| EP-4100395-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | Trobio Therapeutics Pty Ltd (AU) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021155426-A1 | QUINAZOLINE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339866-A1 | Quinazoline compounds and the use thereof in the treatment of cancer | NQO2, TP53, ABL1 | GBA1 1282/4885KDM4E 2051/4885KMT2A 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.